US Sends Experimental Ebola Drug to Congo
The United States is providing experimental antibody treatments to the Democratic Republic of Congo and Uganda. These efforts support clinical trials targeting the Bundibugyo species of ebolavirus. The World Health Organization announced that trials for two potential treatments began in the DRC on Thursday.
What changed
The US has expanded its policy to supply experimental treatments for clinical trials in the DRC and Uganda.
Live updates
-
US Deploys Experimental Ebola Treatment for Bundibugyo Outbreak
confidence 95%The United States is providing experimental antibody treatments to the Democratic Republic of Congo and Uganda. These efforts support clinical trials targeting the Bundibugyo species of ebolavirus. The World Health Organization announced that trials for two potential treatments began in the DRC on Thursday.
What's confirmed:
- The US is deploying the investigational monoclonal antibody therapy MBP134.
- MBP134 was developed through a BARDA partnership with Mapp Biopharmaceutical.
- The World Health Organization announced that trials for two potential treatments began in the DR Congo on Thursday.
- The current outbreak involves the Bundibugyo species of Ebola.
- The US is providing experimental treatments to both the Democratic Republic of Congo and Uganda.
Still unconfirmed:
- Africa CDC is seeking US$18 million to fund Ebola drug trials in the DRC.
- Antivirals from Gilead are to be deployed in the DRC Ebola trial.